Stock INAB IN8BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News IN8bio, Inc.

Equities

INAB

US45674E1091

Delayed Nasdaq
Other stock markets
 12:17:46 2024-06-03 pm EDT 		5-day change 1st Jan Change
1.07 USD -10.08% Intraday chart for IN8bio, Inc. +2.86% -21.74%
May. 24 IN8bio Plans to Report Improvement in Progression-Free Survival of Newly Diagnosed Patients With Glioblastoma Multiforme MT
May. 13 HC Wainwright Adjusts Price Target on IN8bio to $12.50 From $14, Keeps Buy Rating MT

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting
AQ
IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024
AQ
IN8bio Plans to Report Improvement in Progression-Free Survival of Newly Diagnosed Patients With Glioblastoma Multiforme
MT
IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting
AQ
IN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress
AQ
HC Wainwright Adjusts Price Target on IN8bio to $12.50 From $14, Keeps Buy Rating
MT
IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024
AQ
In8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation At Asgct 2024
CI
IN8bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
AQ
IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma
AQ
In8bio, Inc. Doses First Patient in Phase 2 Clinical Trial of Inb-400 in Newly Diagnosed Glioblastoma
CI
IN8bio Announces Oral Presentation at the Upcoming American Society of Gene and Cell Therapy 2024 Annual Meeting
AQ
IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
AQ
IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
AQ
Top Premarket Gainers
MT
North American Morning Briefing: Traders Await the CPI Report
DJ
IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024
AQ
IN8bio, Inc. Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024
CI
Laidlaw Initiates Coverage on IN8bio With Buy Rating, $7.50 Price Target
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. INAB Stock
  4. News IN8bio, Inc.